Kang, M. J. et al. Most cancers statistics in Korea: Incidence, mortality, survival, and prevalence in 2019. Most cancers Res. Deal with. 54, 330–344. https://doi.org/10.4143/crt.2022.128 (2022).
Rudin, C. M., Brambilla, E., Faivre-Finn, C. & Sage, J. Small-cell lung most cancers. Nat. Rev. Dis. Primers 7, 3. https://doi.org/10.1038/s41572-020-00235-0 (2021).
Bogart, J. A., Waqar, S. N. & Combine, M. D. Radiation and systemic remedy for limited-stage small-cell lung most cancers. J. Clin. Oncol. 40, 661–670. https://doi.org/10.1200/jco.21.01639 (2022).
Woodard, G. A., Jones, Okay. D. & Jablons, D. M. Lung most cancers staging and prognosis. Most cancers Deal with. Res. 170, 47–75. https://doi.org/10.1007/978-3-319-40389-2_3 (2016).
Nasim, F., Sabath, B. F. & Eapen, G. A. Lung most cancers. Med. Clin. North Am. 103, 463–473. https://doi.org/10.1016/j.mcna.2018.12.006 (2019).
Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Most cancers-related irritation. Nature 454, 436–444. https://doi.org/10.1038/nature07205 (2008).
Kao, D. D. et al. Neutrophil-to-lymphocyte ratio as a predictor of surgical outcomes in head and neck most cancers. Head Neck 45, 1903–1912. https://doi.org/10.1002/hed.27402 (2023).
Li, P., Li, H., Ding, S. & Zhou, J. NLR, PLR, LMR and MWR as diagnostic and prognostic markers for laryngeal carcinoma. Am. J. Transl. Res. 14, 3017–3027 (2022).
Hirahara, T. et al. Mixed neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in sufferers with superior gastric most cancers. BMC Most cancers 19, 672. https://doi.org/10.1186/s12885-019-5903-y (2019).
Xia, W. Okay. et al. Prognostic efficiency of pre-treatment NLR and PLR in sufferers affected by osteosarcoma. World J. Surg. Oncol. 14, 127. https://doi.org/10.1186/s12957-016-0889-2 (2016).
Ma, J. et al. Neutrophil-to-lymphocyte Ratio (NLR) as a predictor for recurrence in sufferers with stage III melanoma. Sci. Rep. 8, 4044. https://doi.org/10.1038/s41598-018-22425-3 (2018).
Jafri, S. H., Shi, R. & Mills, G. Advance lung most cancers irritation index (ALI) at prognosis is a prognostic marker in sufferers with metastatic non-small cell lung most cancers (NSCLC): A retrospective evaluate. BMC Most cancers 13, 158. https://doi.org/10.1186/1471-2407-13-158 (2013).
He, X. et al. Superior lung most cancers irritation index, a brand new prognostic rating, predicts end result in sufferers with small-cell lung most cancers. Clin. Lung Most cancers 16, e165-171. https://doi.org/10.1016/j.cllc.2015.03.005 (2015).
Zhang, X., Wang, D., Solar, T., Li, W. & Dang, C. Superior lung most cancers irritation index (ALI) predicts prognosis of sufferers with gastric most cancers after surgical resection. BMC Most cancers 22, 684. https://doi.org/10.1186/s12885-022-09774-z (2022).
Hu, Z. et al. Superior lung most cancers irritation index is a prognostic issue of sufferers with small-cell lung most cancers following surgical resection. Most cancers Manag. Res. 13, 2047–2055. https://doi.org/10.2147/cmar.S295952 (2021).
Budczies, J. et al. Cutoff Finder: A complete and easy Net utility enabling fast biomarker cutoff optimization. PLoS ONE 7, e51862. https://doi.org/10.1371/journal.pone.0051862 (2012).
Sumiyoshi, I. et al. Excessive lymphocyte population-related predictive components for a long-term response in non-small cell lung most cancers sufferers handled with pemetrexed: A retrospective observational research. J. Transl. Med. 19, 92. https://doi.org/10.1186/s12967-021-02761-1 (2021).
Tune, M. et al. The superior lung most cancers irritation index is the optimum inflammatory biomarker of total survival in sufferers with lung most cancers. J. Cachexia Sarcopenia Muscle 13, 2504–2514. https://doi.org/10.1002/jcsm.13032 (2022).
Diakos, C. I., Charles, Okay. A., McMillan, D. C. & Clarke, S. J. Most cancers-related irritation and therapy effectiveness. Lancet Oncol. 15, e493-503. https://doi.org/10.1016/s1470-2045(14)70263-3 (2014).
Shamamian, P. et al. Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: A job for inflammatory cells in tumor invasion and angiogenesis. J. Cell Physiol 189, 197–206. https://doi.org/10.1002/jcp.10014 (2001).
Balkwill, F. & Mantovani, A. Irritation and most cancers: Again to Virchow?. Lancet 357, 539–545. https://doi.org/10.1016/s0140-6736(00)04046-0 (2001).
Jabłońska, E. et al. TNF-alpha, IL-6 and their soluble receptor serum ranges and secretion by neutrophils in most cancers sufferers. Arch. Immunol. Ther. Exp. (Warsz) 49, 63–69 (2001).
Lissoni, P. et al. Efficacy of most cancers chemotherapy in relation to the pretreatment variety of lymphocytes in sufferers with metastatic stable tumors. Int. J. Biol. Markers 19, 135–140. https://doi.org/10.1177/172460080401900208 (2004).
Eerola, A. Okay., Soini, Y. & Pääkkö, P. A excessive variety of tumor-infiltrating lymphocytes are related to a small tumor dimension, low tumor stage, and a positive prognosis in operated small cell lung carcinoma. Clin. Most cancers Res. 6, 1875–1881 (2000).
Arina, A., Gutiontov, S. I. & Weichselbaum, R. R. Radiotherapy and immunotherapy for most cancers: From “systemic” to “multisite”. Clin. Most cancers Res. 26, 2777–2782. https://doi.org/10.1158/1078-0432.Ccr-19-2034 (2020).
Jeong, H., Bok, S., Hong, B. J., Choi, H. S. & Ahn, G. O. Radiation-induced immune responses: Mechanisms and therapeutic views. Blood Res. 51, 157–163. https://doi.org/10.5045/br.2016.51.3.157 (2016).
Chen, D. et al. Pre-radiotherapy systemic immune irritation index related to total survival in sufferers with superior EGFR mutant non-small cell lung most cancers receiving thoracic radiotherapy. Clin. Transl. Oncol. 25, 226–235. https://doi.org/10.1007/s12094-022-02936-2 (2023).
Luo, H. et al. Systemic irritation biomarkers predict survival in sufferers of early stage non-small cell lung most cancers handled with stereotactic ablative radiotherapy—a single middle expertise. J. Most cancers 9, 182–188. https://doi.org/10.7150/jca.21703 (2018).
Park, E. Y. et al. Prognostic worth of neutrophil-to-lymphocyte ratio in domestically superior non-small cell lung most cancers handled with concurrent chemoradiotherapy. Radiat. Oncol. J. 37, 166–175. https://doi.org/10.3857/roj.2019.00220 (2019).
Tong, Y. S., Tan, J., Zhou, X. L., Tune, Y. Q. & Tune, Y. J. Systemic immune-inflammation index predicting chemoradiation resistance and poor end result in sufferers with stage III non-small cell lung most cancers. J. Transl. Med. 15, 221. https://doi.org/10.1186/s12967-017-1326-1 (2017).
Scilla, Okay. A. et al. Neutrophil-lymphocyte ratio is a prognostic marker in sufferers with domestically superior (Stage IIIA and IIIB) non-small cell lung most cancers handled with mixed modality remedy. Oncologist 22, 737–742. https://doi.org/10.1634/theoncologist.2016-0443 (2017).
Rossi, A. et al. Carboplatin- or cisplatin-based chemotherapy in first-line therapy of small-cell lung most cancers: The COCIS meta-analysis of particular person affected person information. J. Clin. Oncol. 30, 1692–1698. https://doi.org/10.1200/jco.2011.40.4905 (2012).
Skarlos, D. V. et al. Randomized comparability of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung most cancers. A Hellenic Co-operative Oncology Group research. Ann. Oncol. 5, 601–607. https://doi.org/10.1093/oxfordjournals.annonc.a058931 (1994).
Pan, Z. et al. Cisplatin or carboplatin? Neutrophil to lymphocyte ratio could function a helpful consider small cell lung most cancers remedy choice. Oncol. Lett. 18, 1513–1520. https://doi.org/10.3892/ol.2019.10459 (2019).
Liu, F., Zhou, S., Tan, L., Jiang, H. & Huang, Y. A retrospective cohort research on pretreated neutrophil-to-lymphocyte ratio and prognosis of small cell lung most cancers: Proof of impact modification by chemotherapy routine. Most cancers Manag. Res. 12, 10341–10352. https://doi.org/10.2147/cmar.S263863 (2020).
Mamdani, H., Matosevic, S., Khalid, A. B., Durm, G. & Jalal, S. I. Immunotherapy in lung most cancers: Present panorama and future instructions. Entrance. Immunol. 13, 823618. https://doi.org/10.3389/fimmu.2022.823618 (2022).
Esposito, G. et al. Immunotherapy in small cell lung most cancers. Cancers https://doi.org/10.3390/cancers12092522 (2020).
El Sayed, R. & Blais, N. Immunotherapy in extensive-stage small cell lung most cancers. Curr. Oncol. 28, 4093–4108. https://doi.org/10.3390/curroncol28050347 (2021).
Welsh, J. W. et al. Section 1/2 trial of pembrolizumab and concurrent chemoradiation remedy for limited-stage SCLC. J. Thorac. Oncol. 15, 1919–1927. https://doi.org/10.1016/j.jtho.2020.08.022 (2020).
Liu, S. V. et al. Up to date total survival and PD-L1 subgroup evaluation of sufferers with extensive-stage small-cell lung most cancers handled with atezolizumab, carboplatin, and etoposide (IMpower133). J. Clin. Oncol. 39, 619–630. https://doi.org/10.1200/jco.20.01055 (2021).
Liu, J. et al. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict scientific outcomes in sufferers with metastatic non-small-cell lung most cancers handled with nivolumab. J. Clin. Lab. Anal. 33, e22964. https://doi.org/10.1002/jcla.22964 (2019).
Ksienski, D. et al. Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for superior non-small cell lung most cancers sufferers with excessive PD-L1 tumor expression receiving pembrolizumab. Transl. Lung Most cancers Res. 10, 355–367. https://doi.org/10.21037/tlcr-20-541 (2021).
Hasegawa, T. et al. Affiliation of excessive neutrophil-to-lymphocyte ratio with poor outcomes of pembrolizumab remedy in high-PD-L1-expressing non-small cell lung most cancers. Anticancer Res. 39, 6851–6857. https://doi.org/10.21873/anticanres.13902 (2019).
Shiroyama, T. et al. Pretreatment superior lung most cancers irritation index (ALI) for predicting early development in nivolumab-treated sufferers with superior non-small cell lung most cancers. Most cancers Med. 7, 13–20. https://doi.org/10.1002/cam4.1234 (2018).
Mountzios, G. et al. Affiliation of the superior lung most cancers irritation index (ALI) with immune checkpoint inhibitor efficacy in sufferers with superior non-small-cell lung most cancers. ESMO Open 6, 100254. https://doi.org/10.1016/j.esmoop.2021.100254 (2021).
Yilmaz, H. & Yersal, Ö. Prognostic significance of novel inflammatory markers in extensive-stage small-cell lung most cancers. J. Most cancers Res. Ther. 18, 691–696. https://doi.org/10.4103/jcrt.jcrt_1937_21 (2022).
Miller, Okay. L. et al. Routine use of roughly 60 Gy once-daily thoracic irradiation for sufferers with limited-stage small-cell lung most cancers. Int. J. Radiat. Oncol. Biol. Phys. 56, 355–359. https://doi.org/10.1016/s0360-3016(02)04493-0 (2003).
Roof, Okay. S., Fidias, P., Lynch, T. J., Ancukiewicz, M. & Choi, N. C. Radiation dose escalation in limited-stage small-cell lung most cancers. Int. J. Radiat. Oncol. Biol. Phys. 57, 701–708. https://doi.org/10.1016/s0360-3016(03)00715-6 (2003).
